Results of a matched adjusted trial comparing acalabrutinib versus ibrutinib for treatment of relapsed MCL.
Home / Resource Library / Matching-adjusted indirect comparison of Acalabrutinib versus Ibrutinib in relapsed/refractory mantle cell lymphoma